- Home
- TMCI vs ZBIO Comparison
TMCI vs ZBIO Comparison
Compare TMCI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMCI
- ZBIO
- Stock Information
- Founded
- TMCI 2014
- ZBIO 2019
- Country
- TMCI United States
- ZBIO United States
- Employees
- TMCI N/A
- ZBIO N/A
- Industry
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ZBIO
- Sector
- TMCI Health Care
- ZBIO
- Exchange
- TMCI Nasdaq
- ZBIO NYSE
- Market Cap
- TMCI 371.1M
- ZBIO 389.2M
- IPO Year
- TMCI 2021
- ZBIO 2024
- Fundamental
- Price
- TMCI $6.18
- ZBIO $10.03
- Analyst Decision
- TMCI Hold
- ZBIO Strong Buy
- Analyst Count
- TMCI 6
- ZBIO 7
- Target Price
- TMCI $9.18
- ZBIO $32.29
- AVG Volume (30 Days)
- TMCI 325.4K
- ZBIO 223.0K
- Earning Date
- TMCI 08-05-2025
- ZBIO 08-16-2025
- Dividend Yield
- TMCI N/A
- ZBIO N/A
- EPS Growth
- TMCI N/A
- ZBIO N/A
- EPS
- TMCI N/A
- ZBIO N/A
- Revenue
- TMCI $210,819,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- TMCI $10.61
- ZBIO $206.00
- Revenue Next Year
- TMCI $10.36
- ZBIO $41.92
- P/E Ratio
- TMCI N/A
- ZBIO N/A
- Revenue Growth
- TMCI 7.54
- ZBIO N/A
- 52 Week Low
- TMCI $4.54
- ZBIO $5.83
- 52 Week High
- TMCI $10.79
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- TMCI 55.03
- ZBIO N/A
- Support Level
- TMCI $5.54
- ZBIO N/A
- Resistance Level
- TMCI $6.24
- ZBIO N/A
- Average True Range (ATR)
- TMCI 0.31
- ZBIO 0.00
- MACD
- TMCI 0.09
- ZBIO 0.00
- Stochastic Oscillator
- TMCI 90.11
- ZBIO 0.00
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.